Portal de Periódicos da CAPES

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

2022; BioMed Central; Volume: 20; Issue: 1 Linguagem: Inglês

10.1186/s12916-022-02312-5

1741-7015

Maren Schubert, Federico Bertoglio, Stephan Steinke, Philip Alexander Heine, Mario Alberto Ynga-Durand, Henrike Maaß, Josè Camilla Sammartino, Irene Cassaniti, Fanglei Zuo, Likun Du, Janin Korn, Marko Milošević, Esther Veronika Wenzel, Fran Krstanović, Saskia Polten, Marina Pribanić Matešić, Ilija Brizić, Fausto Baldanti, Lennart Hammarström, Stefan Dübel, Alan S̆ustić, Harold Marcotte, Monika Strengert, Alen Protić, Antonio Piralla, Qiang Pan‐Hammarström, Luka Čičin‐Šain, Michael Hust,

Bacillus and Francisella bacterial research

The COVID-19 pandemic is caused by the betacoronavirus SARS-CoV-2. In November 2021, the Omicron variant was discovered and immediately classified as a variant of concern (VOC), since it shows substantially more mutations in the spike protein than any previous variant, especially in the receptor-binding domain (RBD). We analyzed the binding of the Omicron RBD to the human angiotensin-converting enzyme-2 receptor (ACE2) and the ability of human sera from COVID-19 patients or vaccinees in comparison to Wuhan, Beta, or Delta RBD variants.